Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory...
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory...
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published...
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for...
Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 PR Newswire EMERYVILLE...
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results PR...
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With...
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.